IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,194 shares of the medical research company’s stock after selling 374 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in IQVIA were worth $675,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Versant Capital Management Inc grew its stake in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA during the 2nd quarter worth approximately $27,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA during the 2nd quarter worth approximately $29,000. Rise Advisors LLC purchased a new position in IQVIA during the 1st quarter worth approximately $31,000. Finally, Riverview Trust Co purchased a new position in IQVIA during the 1st quarter worth approximately $32,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on IQV. Royal Bank of Canada began coverage on IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price on the stock. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Evercore ISI lifted their target price on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Finally, Barclays lifted their target price on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Stock Performance

Shares of IQV stock opened at $229.84 on Friday. The stock has a fifty day moving average price of $240.74 and a 200 day moving average price of $232.55. The stock has a market cap of $41.90 billion, a PE ratio of 31.40, a P/E/G ratio of 2.18 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.22 earnings per share. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.